These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 18270334)

  • 1. Time to remove the subspecialty blinders: breast cancer does not exist in isolation.
    Giordano SH; Hortobagyi GN
    J Natl Cancer Inst; 2008 Feb; 100(4):230-1. PubMed ID: 18270334
    [No Abstract]   [Full Text] [Related]  

  • 2. World's largest breast cancer treatment trial supports anastrozole use.
    Oncology (Williston Park); 2002 Jan; 16(1):63. PubMed ID: 11831610
    [No Abstract]   [Full Text] [Related]  

  • 3. Extended adjuvant therapy for breast cancer--how much is enough?
    Prowell TM; Stearns V
    J Natl Cancer Inst; 2007 Dec; 99(24):1825-7. PubMed ID: 18073372
    [No Abstract]   [Full Text] [Related]  

  • 4. [The ATAC study on adjuvants in breast cancer].
    Bravi S
    Suppl Tumori; 2004; 3(4):S15. PubMed ID: 15206200
    [No Abstract]   [Full Text] [Related]  

  • 5. Letrozole or tamoxifen in early breast cancer.
    Erban JK
    N Engl J Med; 2006 Apr; 354(14):1528-30; author reply 1528-30. PubMed ID: 16602148
    [No Abstract]   [Full Text] [Related]  

  • 6. Quality of life in a randomized control trial? Comments concerning MA 17.
    This P; de la Rochefordière A; Bredart A; Asselain B; Poinsot R; Dolbeault S; Sigal-Zafrani B
    J Clin Oncol; 2006 Aug; 24(24):4038; author reply 4038-9. PubMed ID: 16921063
    [No Abstract]   [Full Text] [Related]  

  • 7. Adjuvant aromatase inhibitors for breast cancer.
    Howell A
    Lancet; 2005 Aug 6-12; 366(9484):431-3. PubMed ID: 16084234
    [No Abstract]   [Full Text] [Related]  

  • 8. Adjuvant use of anastrozole in breast cancer.
    Cuzick J; Buzdar A; Baum M; Bianco R; Coleman R; Constenla M; Distler W; Dowsett M; Forbes J; Guastalla JP; Houghton J; Williams N; Howell A; Locker G; MacKey J; Sainsbury R; Tobias J
    J Clin Oncol; 2004 Apr; 22(8):1524-6; author reply 1526-7. PubMed ID: 15084628
    [No Abstract]   [Full Text] [Related]  

  • 9. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: the example of clinical studies].
    Giannessi PG
    Suppl Tumori; 2004; 3(4):S73-4. PubMed ID: 15206218
    [No Abstract]   [Full Text] [Related]  

  • 10. Tamoxifen vs the aromatase inhibitors: news from San Antonio, 2001.
    Munster PN; Horton J
    Cancer Control; 2001; 8(6):478-9. PubMed ID: 11807416
    [No Abstract]   [Full Text] [Related]  

  • 11. ATAC trial update.
    de Castro G
    Lancet; 2005 Apr 2-8; 365(9466):1225; author reply 1225-6. PubMed ID: 15811448
    [No Abstract]   [Full Text] [Related]  

  • 12. [Letrozole vs. placebo after adjuvant tamoxifen in postmenopausal breast cancer: the MA-17 study].
    Gori S; Anastasi P; Marrocolo F
    Suppl Tumori; 2004; 3(4):S27-31. PubMed ID: 15206206
    [No Abstract]   [Full Text] [Related]  

  • 13. Re: Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.
    Vakaet L
    J Natl Cancer Inst; 2006 Aug; 98(16):1162; author reply 1162-3. PubMed ID: 16912269
    [No Abstract]   [Full Text] [Related]  

  • 14. [The ATAC study on adjuvants in breast cancer. What kind of repercussions will it have on clinical practice?].
    Gamucci T
    Suppl Tumori; 2004; 3(4):S16. PubMed ID: 15206201
    [No Abstract]   [Full Text] [Related]  

  • 15. [The optimal duration of adjuvant therapy in breast cancer: what kind of evidence? Hormone therapy: what kind of evidence?].
    Angiolini C
    Suppl Tumori; 2004; 3(4):S75-6. PubMed ID: 15206219
    [No Abstract]   [Full Text] [Related]  

  • 16. Adjuvant aromatase inhibitors: are we there yet?
    Fleming GF
    Cancer; 2003 Nov; 98(9):1779-81. PubMed ID: 14584057
    [No Abstract]   [Full Text] [Related]  

  • 17. Letrozole compared with tamoxifen as initial adjuvant therapy for breast cancer.
    Buzdar AU
    J Clin Oncol; 2007 May; 25(15):2147-8; author reply 2148. PubMed ID: 17513830
    [No Abstract]   [Full Text] [Related]  

  • 18. [Campaign against breast cancer. Are aromatase inhibitors the better choice? (interview by Dr. Dorothea Dlugosch)].
    Bruntsch U
    MMW Fortschr Med; 2002 Sep; 144(38):20. PubMed ID: 12395697
    [No Abstract]   [Full Text] [Related]  

  • 19. An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole.
    Tobias JS; Howell A
    Eur J Cancer; 2004 Aug; 40(12):1913. PubMed ID: 15288295
    [No Abstract]   [Full Text] [Related]  

  • 20. Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer: methodologic issues.
    Winquist E; Bramwell V; Vandenberg T
    J Clin Oncol; 2002 Sep; 20(17):3748-9; author reply 3749-50. PubMed ID: 12202679
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.